NASDAQ:ABMDABIOMED Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ABIOMED, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $152.78 +2.52 (+1.68 %) (As of 04/8/2020 08:19 AM ET) Add Compare Share Today's Range$151.60Now: $152.78▼$162.2350-Day Range$130.51MA: $150.30▼$169.0052-Week Range$119.01Now: $152.78▼$286.50Volume936,784 shsAverage Volume901,702 shsMarket Capitalization$6.88 billionP/E Ratio28.72Dividend YieldN/ABeta0.61 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingABIOMED has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 5 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $224.80, ABIOMED has a potential upside of 47.1% from its current price of $152.78.Amount of Analyst CoverageABIOMED has only been the subject of 4 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesABIOMED has received 519 “outperform” votes. (Add your “outperform” vote.)Underperform VotesABIOMED has received 466 “underperform” votes. (Add your “underperform” vote.)Community SentimentABIOMED has received 52.69% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote “Outperform” if you believe ABMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldABIOMED does not currently pay a dividend.Dividend GrowthABIOMED does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ABIOMED insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.40% of the stock of ABIOMED is held by insiders.Percentage Held by Institutions98.17% of the stock of ABIOMED is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ABIOMED are expected to grow by 8.50% in the coming year, from $4.12 to $4.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ABIOMED is 28.72, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 12.02.Price to Earnings Ratio vs. SectorThe P/E ratio of ABIOMED is 28.72, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.40.Price to Earnings Growth RatioABIOMED has a PEG Ratio of 1.51. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioABIOMED has a P/B Ratio of 7.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ABMD Previous Symbol CUSIP00365410 CIK815094 Webhttp://www.abiomed.com/ Phone978-646-1400Debt Debt-to-Equity RatioN/A Current Ratio5.04 Quick Ratio4.32Price-To-Earnings Trailing P/E Ratio28.72 Forward P/E Ratio37.08 P/E Growth1.51 Sales & Book Value Annual Sales$769.43 million Price / Sales8.95 Cash Flow$4.32 per share Price / Cash Flow35.37 Book Value$20.78 per share Price / Book7.35Profitability EPS (Most Recent Fiscal Year)$3.60 Net Income$259.02 million Net Margins29.14% Return on Equity19.53% Return on Assets17.26%Miscellaneous Employees1,371 Outstanding Shares45,063,000Market Cap$6.88 billion Next Earnings Date5/7/2020 (Estimated) OptionableOptionable Receive ABMD News and Ratings via Email Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ABMD Rates by TradingView ABIOMED (NASDAQ:ABMD) Frequently Asked Questions How has ABIOMED's stock been impacted by COVID-19 (Coronavirus)? ABIOMED's stock was trading at $151.13 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ABMD shares have increased by 1.1% and is now trading at $152.78. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of ABIOMED? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ABIOMED. When is ABIOMED's next earnings date? ABIOMED is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for ABIOMED. How were ABIOMED's earnings last quarter? ABIOMED, Inc. (NASDAQ:ABMD) issued its quarterly earnings results on Thursday, February, 6th. The medical equipment provider reported $1.51 EPS for the quarter, beating the Zacks' consensus estimate of $1.09 by $0.42. The medical equipment provider had revenue of $221.60 million for the quarter, compared to the consensus estimate of $226.92 million. ABIOMED had a net margin of 29.14% and a return on equity of 19.53%. The business's quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.97 earnings per share. View ABIOMED's earnings history. What guidance has ABIOMED issued on next quarter's earnings? ABIOMED issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, February, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $846-877 million, compared to the consensus revenue estimate of $885.43 million. What price target have analysts set for ABMD? 9 brokers have issued 1 year target prices for ABIOMED's shares. Their forecasts range from $149.00 to $340.00. On average, they anticipate ABIOMED's stock price to reach $224.80 in the next year. This suggests a possible upside of 47.1% from the stock's current price. View analysts' price targets for ABIOMED. What are Wall Street analysts saying about ABIOMED stock? Here are some recent quotes from research analysts about ABIOMED stock: 1. According to Zacks Investment Research, "ABIOMED wrapped up fourth-quarter fiscal 2019 on a mixed note. Competition in the MedTech industry is intense. Pricing pressure and foreign currency headwinds persist. ABIOMED has underperformed the industry in a year’s time. However, the company continues to gain from its flagship Impella, which saw a strong quarter. Impella’s patient success stories and increasing global adoption are added positives. Revenues from Japan also skyrocketed in the quarter. Considerable expansion in the operating margin buoys optimism. Meanwhile, surging R&D expenses show increasing focus on innovation. In fact, the company continues to invest in training and education. The recent CE Mark of the Impella Connect is encouraging as well. The company’s balance sheet is debt-free." (5/8/2019) 2. BTIG Research analysts commented, "Term; Trimming PT to $340 From $400 Abiomed missed estimates in the quarter, delivering sales of $207M, short of consensus’ $219M forecast. Most of the weakness was U.S. driven, due to a weak cath lab (also seen in peer results) and to a greater extent, mix disruption leading to mgmt’s disproportionate focus away from protected PCI/elective procedures. To reflect these pressures, mgmt’s initial FY20 outlook calls for revenue growth of 17-23%, 6% below what mgmt (and we) would’ve considered more likely (and exactly the exact magnitude of the FQ4 shortfall). Mgmt outlined a number of initiatives to address these issues and noted that April is reportedly promising. The fact that mgmt still remains confident in addressable market and has left room to revise guidance during its next earnings call suggest there is good chance of upside." (5/7/2019) Has ABIOMED been receiving favorable news coverage? News coverage about ABMD stock has been trending very negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ABIOMED earned a news impact score of -3.3 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutABIOMED. Who are some of ABIOMED's key competitors? Some companies that are related to ABIOMED include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Stryker (SYK), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Insulet (PODD) and Masimo (MASI). What other stocks do shareholders of ABIOMED own? Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Arista Networks (ANET), Netflix (NFLX), Align Technology (ALGN), Square (SQ), salesforce.com (CRM), bluebird bio (BLUE) and Paypal (PYPL). Who are ABIOMED's key executives? ABIOMED's management team includes the following people: Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 52)Dr. David M. Weber, Chief Operating Officer (Age 58)Mr. Michael G. Howley, VP & GM of Global Sales (Age 55)Mr. William J. Bolt, Exec. Officer (Age 67)Mr. Ian McLeod, VP & Corp. Controller What is ABIOMED's stock symbol? ABIOMED trades on the NASDAQ under the ticker symbol "ABMD." Who are ABIOMED's major shareholders? ABIOMED's stock is owned by a variety of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.02%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View institutional ownership trends for ABIOMED. Which major investors are buying ABIOMED stock? ABMD stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. View insider buying and selling activity for ABIOMED. How do I buy shares of ABIOMED? Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ABIOMED's stock price today? One share of ABMD stock can currently be purchased for approximately $152.78. How big of a company is ABIOMED? ABIOMED has a market capitalization of $6.88 billion and generates $769.43 million in revenue each year. The medical equipment provider earns $259.02 million in net income (profit) each year or $3.60 on an earnings per share basis. ABIOMED employs 1,371 workers across the globe. View additional information about ABIOMED. What is ABIOMED's official website? The official website for ABIOMED is http://www.abiomed.com/. How can I contact ABIOMED? ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected] This page was last updated on 4/8/2020 by MarketBeat.com StaffFeatured Article: Blue-Chip Stocks
